Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
ADAP | US
Overview
Corporate Details
- ISIN(s):
- US00653A1079
- LEI:
- Country:
- United States of America
- Address:
- 60 JUBILEE AVENUE, 0 ABINGDON, OXFORDSHIRE
- Website:
- https://www.adaptimmune.com/
- Sector:
- Manufacturing
Description
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Adaptimmune Therapeutics PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adaptimmune Therapeutics PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adaptimmune Therapeutics PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
